KR20220133866A - 디아릴 매크로시클릭 화합물을 수반하는 병용 요법 - Google Patents

디아릴 매크로시클릭 화합물을 수반하는 병용 요법 Download PDF

Info

Publication number
KR20220133866A
KR20220133866A KR1020227021852A KR20227021852A KR20220133866A KR 20220133866 A KR20220133866 A KR 20220133866A KR 1020227021852 A KR1020227021852 A KR 1020227021852A KR 20227021852 A KR20227021852 A KR 20227021852A KR 20220133866 A KR20220133866 A KR 20220133866A
Authority
KR
South Korea
Prior art keywords
alkyl
cancer
compound
kras
inhibits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227021852A
Other languages
English (en)
Korean (ko)
Inventor
웨이 뎅
다용 자이
로라 로돈
브라이언 더블유. 머레이
진그롱 제이. 쿠이
Original Assignee
터닝 포인트 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 터닝 포인트 테라퓨틱스, 인크. filed Critical 터닝 포인트 테라퓨틱스, 인크.
Publication of KR20220133866A publication Critical patent/KR20220133866A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227021852A 2019-11-27 2020-11-25 디아릴 매크로시클릭 화합물을 수반하는 병용 요법 Pending KR20220133866A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962941026P 2019-11-27 2019-11-27
US62/941,026 2019-11-27
US202062981822P 2020-02-26 2020-02-26
US62/981,822 2020-02-26
US202063005681P 2020-04-06 2020-04-06
US63/005,681 2020-04-06
PCT/US2020/062390 WO2021108682A1 (en) 2019-11-27 2020-11-25 Combination therapy involving diaryl macrocyclic compounds

Publications (1)

Publication Number Publication Date
KR20220133866A true KR20220133866A (ko) 2022-10-05

Family

ID=76129920

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227021852A Pending KR20220133866A (ko) 2019-11-27 2020-11-25 디아릴 매크로시클릭 화합물을 수반하는 병용 요법

Country Status (12)

Country Link
US (2) US11654145B2 (https=)
EP (1) EP4065125A4 (https=)
JP (1) JP7670711B2 (https=)
KR (1) KR20220133866A (https=)
CN (1) CN114901286B (https=)
AU (1) AU2020391222A1 (https=)
BR (1) BR112022010278A2 (https=)
CA (1) CA3162632A1 (https=)
IL (1) IL293206A (https=)
MX (1) MX2022006500A (https=)
TW (1) TW202133855A (https=)
WO (1) WO2021108682A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021154929A1 (en) * 2020-01-31 2021-08-05 Verastem, Inc. Combination therapy for treating abnormal cell growth
US20220323446A1 (en) * 2021-03-17 2022-10-13 Amgen Inc. Sotorasib dosing regimen
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2025148858A1 (zh) * 2024-01-08 2025-07-17 应世生物科技(南京)有限公司 FAK抑制剂和Pan-RAS抑制剂
WO2025157162A1 (zh) * 2024-01-22 2025-07-31 应世生物科技(南京)有限公司 Fak抑制剂与kras g12c抑制剂的联用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010319322A1 (en) * 2009-11-13 2012-05-31 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
ES2933350T3 (es) * 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
AU2016287568B2 (en) * 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
RU2765181C2 (ru) * 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
EP3368039A1 (en) * 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
US20190134056A1 (en) * 2017-03-10 2019-05-09 The Trustees Of The Stevens Institute Of Technolog K-ras mutations and antagonists
AU2018273356B2 (en) 2017-05-22 2021-09-16 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
LT3710439T (lt) 2017-11-15 2023-05-10 Mirati Therapeutics, Inc. Kras g12c inhibitoriai
JP7060694B2 (ja) * 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
ES3017461T3 (en) 2018-09-10 2025-05-13 Mirati Therapeutics Inc Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
CN110256421A (zh) * 2019-06-26 2019-09-20 微境生物医药科技(上海)有限公司 Kras-g12c抑制剂
MX2022006366A (es) * 2019-11-27 2022-06-22 Turning Point Therapeutics Inc Terapia de combinacion que implica compuestos de diarilo macrociclico.
WO2021148581A1 (en) * 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Also Published As

Publication number Publication date
EP4065125A4 (en) 2024-01-03
JP2023505056A (ja) 2023-02-08
IL293206A (en) 2022-07-01
AU2020391222A1 (en) 2022-06-30
US11654145B2 (en) 2023-05-23
US20240033266A1 (en) 2024-02-01
CA3162632A1 (en) 2021-06-03
CN114901286B (zh) 2024-05-10
WO2021108682A1 (en) 2021-06-03
MX2022006500A (es) 2022-07-04
CN114901286A (zh) 2022-08-12
EP4065125A1 (en) 2022-10-05
JP7670711B2 (ja) 2025-04-30
US20210220364A1 (en) 2021-07-22
TW202133855A (zh) 2021-09-16
BR112022010278A2 (pt) 2022-10-04

Similar Documents

Publication Publication Date Title
JP7086251B2 (ja) ヘテロ環式化合物およびそれらの使用
JP7670711B2 (ja) ジアリール大環状化合物を含む併用療法
JP7193475B2 (ja) ジアリール大環状化合物を含む併用療法
CN104271159B (zh) 利用tor激酶抑制剂联合治疗来治疗非小细胞肺癌的方法
CN108026109A (zh) 手性二芳基大环及其用途
KR20220134522A (ko) 디아릴 매크로시클릭 화합물을 수반하는 병용 요법
JP2022507514A (ja) Ｅｒｋインヒビター及びその使用
EA030808B1 (ru) ПРИМЕНЕНИЕ 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1Н-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА В ЛЕЧЕНИИ МУЛЬТИФОРМНОЙ ГЛИОБЛАСТОМЫ
US20220072003A1 (en) Organic compounds
WO2018127195A1 (zh) 取代的稠合杂芳基化合物作为激酶抑制剂及其应用
CN118159534A (zh) 抑制PI3K同工型α的化合物和用于治疗癌症的方法
CN108473472B (zh) 作为p70s6激酶抑制剂的2-氨基喹唑啉衍生物
TW202026001A (zh) 用於癌症治療之ＴＧＦβ抑制劑及ＣＤＫ抑制劑之組合
WO2021061695A1 (en) Treatment of egfr mutant-related cancers using a combination of egfr and cdk4/6 inhibitors
RU2784853C2 (ru) Комбинационная терапия с применением диарильных макроциклических соединений
EP4441052B1 (en) Compounds
HK40128998A (zh) 治疗癌症的方法
HK1254606B (zh) 手性二芳基大环及其用途
HK1199244B (en) Combinations of akt inhibitor compounds and vemurafenib, and methods of use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902